Organovo Holdings, Inc. (ONVO) - NYSEMKT
  • Fri, Jun. 10, 6:25 AM
    • Organovo Holdings (ONVO) FQ4 results: Revenues: $0.5M (+66.7%); R&D Expense: $4.5M (+25.0%); SG&A: $4.4M (-4.3%); Net Loss: ($8.4M) (-7.7%); Loss Per Share : ($0.09) (+10.0%).
    • FY2016 results: Revenues: $1.5M (+150.0%); R&D Expense: $18M (+39.5%); SG&A: $22.1M (+23.5%); Net Loss: ($38.6M) (-28.2%); Loss Per Share: ($0.43) (-13.2%); Quick Assets: $62.1M (+24.0%); CF Ops: ($29.4M) (-50.0%).
    • FY2017 Guidance: Total Revenue: $4M - 6M; Net Cash Utilization: $32.5M - 36.5M.
    | Fri, Jun. 10, 6:25 AM | 2 Comments
  • Thu, Jun. 9, 4:10 PM
    • Organovo Holdings (NYSEMKT:ONVO): FQ4 EPS of -$0.09 beats by $0.02.
    • Revenue of $0.55M (+103.7% Y/Y) beats by $0.25M.
    • Press Release
    | Thu, Jun. 9, 4:10 PM
  • Mon, Feb. 8, 5:01 PM
    • Despite its bullish prognostications about $100M+ revenue potential, micro cap Organovo (NYSEMKT:ONVO) continues to struggle to grow sales. Its top line for fiscal Q3 was only $0.3M. It is pinning its hopes on its exVive3D Human Liver Tissue and service, launched in November. It asserts that the liver assay alone will generate tens of millions in revenue. Exactly when is uncertain.
    • Commercial contracting for its kidney tissue product should commence in Q3.
    • Its fiscal 2016 outlook for revenue from previously reported contract bookings has been lowered to $0.7M - 0.9M from $1.2M - 1.4M. Net cash utilization should be $32M - 34M. As of December 31, the company's quick assets totaled $70M.
    • Previously: Organovo Holdings EPS in-line, misses on revenue (Feb. 8)
    | Mon, Feb. 8, 5:01 PM | 4 Comments
  • Mon, Feb. 8, 4:20 PM
    • Organovo Holdings (NYSEMKT:ONVO): FQ3 EPS of -$0.11 in-line.
    • Revenue of $0.33M (+106.3% Y/Y) misses by $0.11M.
    • Press Release
    | Mon, Feb. 8, 4:20 PM
  • Tue, Jan. 19, 9:37 AM
    • Organovo (ONVO +1.1%) Chief Financial Officer Barry Michaels will retire effective March 31, the end of the company's current fiscal year. He has been CFO since August 2011. A successor has yet to be named.
    | Tue, Jan. 19, 9:37 AM | 6 Comments
  • Nov. 10, 2015, 10:52 AM
    • Organovo Holdings (ONVO -6.5%) FQ2 results: Revenues: $0.3M (+500.0%); R&D Expense: $4.7M (+46.9%); SG&A: $6.8M (+17.2%); Net Loss: ($11.3M) (-27.0%); Loss Per Share: ($0.12) (-9.1%); Quick Assets: $76.9M (+53.5%).
    • 2016 Guidance: Total Revenue Recognized From Contract Bookings: $1.2M - 1.4M; Net Cash Utilization: $32M - 36M.
    | Nov. 10, 2015, 10:52 AM | 8 Comments
  • Nov. 9, 2015, 4:18 PM
    • Organovo Holdings (NYSEMKT:ONVO): FQ2 EPS of -$0.12 misses by $0.02.
    • Revenue of $0.3M in-line.
    | Nov. 9, 2015, 4:18 PM | 3 Comments
  • Oct. 2, 2015, 9:12 AM
    | Oct. 2, 2015, 9:12 AM | 1 Comment
  • Sep. 29, 2015, 3:31 PM
    • 3D printer makers 3D Systems (DDD -6.8%), Stratasys (SSYS -9.3%), and Voxeljet (VJET -12.6%) are having another ugly day as markets remain in risk-off mode - the Nasdaq is down 1.2% - and so is 3D-printed tissue developer Organovo (ONVO -14.1%). Save for Voxeljet, volume has been below-average.
    • 3D Systems and Voxeljet have made fresh 52-week lows. YTD performances: DDD -33%, SSYS -69%, VJET -48%, ONVO -64%.
    • Though many shorts undoubtedly now have big paper profits, Voxeljet is the only name in the group to see significant short-covering this year: 3D had 34% of its float shorted as of Sep. 15, Stratasys 28%, Voxeljet 10%, and Organovo 27%.
    | Sep. 29, 2015, 3:31 PM | 8 Comments
  • Sep. 15, 2015, 12:41 PM
    | Sep. 15, 2015, 12:41 PM | 2 Comments
  • Sep. 1, 2015, 4:04 PM
    • Continuing a rough 2015, 3D Systems (DDD -6.6%), Stratasys (SSYS -5.8%), Organovo (ONVO -10.6%), Arcam (OTCPK:AMAVF -6.1%), and Voxeljet (VJET -4.9%) have seen outsized losses on a day the Nasdaq fell 2.9%. Volume was generally below-average.
    • Short interests indicate many shorts with large profits have chosen not to cover: 3D Systems had 35% of its float shorted as of Aug. 14, Stratasys 28%, Organovo 26%, and Voxeljet 11%.
    • Earlier today, Stratasys announced the Objet30 Dental Prime, a 3D printer aimed at smaller dental labs. The company promises the printer's High Quality mode can deliver "intricate, delicate features required for precise fittings on crown, bridge, and prosthetic models" via 16-micron layers.
    • Meanwhile, Organovo CEO Keith Murphy defended his company in a talk with Benzinga - he discussed partnerships with Merck, L'Oreal, and Yale, and downplayed Organovo's FQ1 numbers. "We reported about $300K in revenue for the first quarter, and we're seeing some reaction to that, I would say. The bigger picture is, last quarter we had $2 million in booked contracts. The fact that these (contracts) take a couple of quarters to be recognized as revenue shouldn't surprise anyone."
    | Sep. 1, 2015, 4:04 PM | 14 Comments
  • Aug. 11, 2015, 12:45 PM
    | Aug. 11, 2015, 12:45 PM
  • Aug. 11, 2015, 9:16 AM
    | Aug. 11, 2015, 9:16 AM
  • Aug. 11, 2015, 8:18 AM
    • Regenerative medicine firm Organovo (NYSEMKT:ONVO) slumps 19% in premarket trading on mediocre volume in response to its release of fiscal Q1 results after the close yesterday.
    • Although the company stated that contract bookings for its exVive3D Human Liver Tissue were ~$2M, recorded revenues were only ~$300K, far below the projected "tens of millions" eventual run rate that management believes is achievable.
    • Previously: Organovo says liver tissue will be $100M business (March 13)
    | Aug. 11, 2015, 8:18 AM | 11 Comments
  • Aug. 11, 2015, 8:15 AM
    • Organovo Holdings (ONVO +17.6%) FQ1 results: Revenues: $0.3M (+200.0%); R&D Expense: $4.1M (+46.4%); SG&A: $4.6M (+24.3%); Net Loss: ($8.5M) (-32.8%); Loss Per Share: ($0.10) (-25.0%); Quick Assets: $86M (+71.7%).
    • No guidance given.
    | Aug. 11, 2015, 8:15 AM | 1 Comment
  • Aug. 10, 2015, 4:50 PM
    • Organovo Holdings (NYSEMKT:ONVO): FQ1 EPS of -$0.10 misses by $0.01.
    • Revenue of $0.31M (+210.0% Y/Y) misses by $0.12M.
    | Aug. 10, 2015, 4:50 PM | 10 Comments
Company Description
Organovo Holdings, Inc. is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can... More
Sector: Healthcare
Industry: Medical Laboratories & Research
Country: United States